Hui-Ming Zeng

Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

The phase 2 findings support further evaluation of QY201 at doses of 10 mg BID and 20 mg BID in confirmatory phase 3 trials, and inform dose selection for phase 3 studies.